These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 14565673)

  • 1. Rituximab in heavily pretreated cutaneous B-cell lymphoma.
    Zinzani PL; Stefoni V; Alinari L; Vianelli N; Baccarani M
    Leuk Lymphoma; 2003 Sep; 44(9):1637-8. PubMed ID: 14565673
    [No Abstract]   [Full Text] [Related]  

  • 2. Rituximab in combination with interferon-alpha in relapsed and refractory diffuse large B-cell non-Hodgkin's lymphoma.
    Bertè R; Vallisa D; Civardi G; Moroni CF; Lazzaro A; Cavanna L
    Acta Haematol; 2001; 106(3):141-2. PubMed ID: 11713384
    [No Abstract]   [Full Text] [Related]  

  • 3. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
    Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
    Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 mono- clonal antibody) and interleukin-2.
    Keilholz U; Szelényi H; Siehl J; Foss HD; Knauf W; Thiel E
    Leuk Lymphoma; 1999 Nov; 35(5-6):641-2. PubMed ID: 10609806
    [No Abstract]   [Full Text] [Related]  

  • 5. Modified chop-chemotherapy plus rituximab for diffuse large b-cell lymphoma complicating ataxia-telangiectasia.
    Rossi G; Zecca M; Marchi A; de Stefano P; Sammarchi L; Locatelli F
    Br J Haematol; 2003 Jan; 120(2):369-71. PubMed ID: 12542504
    [No Abstract]   [Full Text] [Related]  

  • 6. Lymphomatoid granulomatosis treated with rituximab and chemotherapy.
    Rao R; Vugman G; Leslie WT; Loew J; Venugopal P
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):658-60; discussion 660. PubMed ID: 16258464
    [No Abstract]   [Full Text] [Related]  

  • 7. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study.
    Jermann M; Jost LM; Taverna Ch; Jacky E; Honegger HP; Betticher DC; Egli F; Kroner T; Stahel RA
    Ann Oncol; 2004 Mar; 15(3):511-6. PubMed ID: 14998858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of cutaneous B-cell lymphoma, leg type, with age-adapted combinations of chemotherapies and rituximab.
    Grange F; Maubec E; Bagot M; Beylot-Barry M; Joly P; Dalle S; Delaporte E; Dereure O; Bachelez H; Vergier B; Petrella T; D'Incan M
    Arch Dermatol; 2009 Mar; 145(3):329-30. PubMed ID: 19289772
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of combination chemotherapy with cefoperazone on non-Hodgkin's lymphoma.
    Natazuka T; Matsui T; Ito M; Sugimoto T; Nakao Y; Fujita T
    Leuk Res; 1992; 16(4):417-8. PubMed ID: 1373460
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of carboplatin with an MEP (mitoxantrone, etoposide and prednisone) regimen for relapsed and CHOP-resistant diffuse large B-cell lymphomas.
    Murohashi I; Kashimura T; Tominaga K; Wakao D; Takahashi T; Akiba M; Kishimoto K; Yoshida K; Yagasaki F; Itoh Y; Sakata T; Kawai N; Itoh K; Suzuki T; Matsuda A; Hirashima K; Bessho M
    Leuk Res; 2002 Mar; 26(3):229-34. PubMed ID: 11792410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.
    Derenzini E; Stefoni V; Pellegrini C; Fina MP; Broccoli A; Venturini F; Gandolfi L; Pileri SA; Martelli M; Petti MC; Perrotti A; De Renzo A; Zaja F; Baccarani M; Zinzani PL
    Leuk Lymphoma; 2009 Nov; 50(11):1824-9. PubMed ID: 19814687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.
    Zinzani PL; Gandolfi L; Broccoli A; Argnani L; Fanti S; Pellegrini C; Stefoni V; Derenzini E; Quirini F; Baccarani M
    Cancer; 2011 Mar; 117(5):1010-8. PubMed ID: 20960498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A case of diffuse large cell lymphoma treated with combination chemotherapy of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) and BEMP (bleomycin, etoposide, mitoxantrone, procarbazine) with complete remission].
    Itoh T; Sakata Y; Suzuki H; Sugimoto N; Sohma N; Kishibe T; Higuchi S; Seino Y
    Gan To Kagaku Ryoho; 1992 Feb; 19(2):241-4. PubMed ID: 1371049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and outcome of patients with diffuse large B cell lymphoma with marrow involvement and preliminary experience of an adult acute lymphoblastic leukemia protocol (NEALL VI) in cyclophosphamide, doxorubicin, vincristine, and prednisolone--rituximab refractory patients.
    Sieniawski M; Bhartia S; Wilkinson J; Proctor SJ
    Leuk Lymphoma; 2009 Oct; 50(10):1726-30. PubMed ID: 19639513
    [No Abstract]   [Full Text] [Related]  

  • 16. Complete and durable remission of refractory mantle cell lymphoma with repeated rituximab monotherapy.
    Ishiyama K; Takami A; Okumura H; Ozaki J; Shimadoi S; Yamanaka S; Nakao S
    Int J Hematol; 2005 May; 81(4):319-22. PubMed ID: 15914363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VNCOP-B plus rituximab in the treatment of diffuse large B-cell lymphoma in the elderly.
    Fina M; Tani M; Stefoni V; Musuraca G; Marchi E; Pellegrini C; Alinari L; Derenzini E; Bacci F; Pileri S; Baccarani M; Zinzani PL
    Leuk Lymphoma; 2007 Nov; 48(11):2167-71. PubMed ID: 17990178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Echocardiographic findings of intracardiac mass.
    Tanaka H; Kawai H; Ishida T; Yoshida A; Yokoyama M
    J Cardiol; 2007 Aug; 50(2):155-7. PubMed ID: 17802700
    [No Abstract]   [Full Text] [Related]  

  • 19. Partial restoration of CD20 protein expression and rituximab sensitivity after treatment with azacitidine in CD20-negative transformed diffuse large B cell lymphoma after using rituximab.
    Hiraga J; Tomita A; Suzuki N; Takagi Y; Narita M; Kagami Y
    Ann Hematol; 2018 Nov; 97(11):2253-2255. PubMed ID: 29725760
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) therapy.
    Isogai R; Fukao M; Kawada A
    J Dermatol; 2007 Aug; 34(8):556-60. PubMed ID: 17683387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.